Phenotypic, ethologically based resolution of spontaneous and D2‐like vs D1‐like agonist‐induced behavioural topography in mice with congenic D3 dopamine receptor “knockout”
暂无分享,去创建一个
Anthony Kinsella | J. Waddington | J. Drago | S. Fuchs | F. N. McNamara | Fergal N McNamara | Jeremiah J Clifford | Orna Tighe | John Drago | Sara Fuchs | David T Croke | John L Waddington | A. Kinsella | O. Tighe | D. Croke | J. Clifford | David T. Croke | Fergal N. McNamara
[1] J. Waddington,et al. Dopaminergic behaviour stereospecifically promoted by the D1 agonist R-SK & F 38393 and selectively blocked by the D1 antagonist SCH 23390 , 2004, Psychopharmacology.
[2] J. Waddington,et al. D1-Like Dopamine Receptors: Molecular Biology and Pharmacology , 2002 .
[3] M. Low,et al. Comparative, Topographically-Based Evaluation of Behavioural Phenotype and Specification of D1-Like:D2 Interactions in a Line of Incipient Congenic Mice with D2 Dopamine Receptor ‘Knockout’ , 2001, Neuropsychopharmacology.
[4] K. Wicke,et al. The dopamine D3 receptor partial agonist, BP 897, is an antagonist at human dopamine D3 receptors and at rat somatodendritic dopamine D3 receptors. , 2001, European journal of pharmacology.
[5] J. Waddington,et al. The psychopharmacology-molecular biology interface: exploring the behavioural roles of dopamine receptor subtypes using targeted gene deletion (‘knockout’) , 2001, Progress in Neuro-Psychopharmacology and Biological Psychiatry.
[6] N. Koshikawa,et al. Topographical assessment and pharmacological characterization of orofacial movements in mice: dopamine D(1)-like vs. D(2)-like receptor regulation. , 2001, European journal of pharmacology.
[7] R. Mailman,et al. Quantification of D1B (D5) receptors in dopamine D1A receptor‐deficient mice , 2001, Synapse.
[8] P. Strange,et al. Antipsychotic drugs: importance of dopamine receptors for mechanisms of therapeutic actions and side effects. , 2001, Pharmacological reviews.
[9] J. Hagan,et al. Pharmacological actions of a novel, high-affinity, and selective human dopamine D(3) receptor antagonist, SB-277011-A. , 2000, The Journal of pharmacology and experimental therapeutics.
[10] K. Berridge,et al. Super‐stereotypy I: Enhancement of a complex movement sequence by systemic dopamine D1 agonists , 2000, Synapse.
[11] P. Fletcher,et al. Modification of dopamine D1 receptor knockout phenotype in mice lacking both dopamine D1 and D3 receptors , 2000 .
[12] M. Millan,et al. S33084, a novel, potent, selective, and competitive antagonist at dopamine D(3)-receptors: I. Receptorial, electrophysiological and neurochemical profile compared with GR218,231 and L741,626. , 2000, The Journal of pharmacology and experimental therapeutics.
[13] J. Waddington,et al. Topographical evaluation of behavioural phenotype in a line of mice with targeted gene deletion of the D2 dopamine receptor , 2000, Neuropharmacology.
[14] A. Undie,et al. Dopaminergic behaviors and signal transduction mediated through adenylate cyclase and phospholipase C pathways , 2000, Neuropharmacology.
[15] R. Hen,et al. Complications associated with genetic background effects in research using knockout mice , 1999, Psychopharmacology.
[16] C. Schmauss,et al. Decreased c-fos Responses to Dopamine D1Receptor Agonist Stimulation in Mice Deficient for D3Receptors* , 1999, The Journal of Biological Chemistry.
[17] R. Depoortère,et al. Dopamine D2 receptor knock-out mice are insensitive to the hypolocomotor and hypothermic effects of dopamine D2/D3 receptor agonists , 1999, Neuropharmacology.
[18] D. Sibley,et al. Conservation of behavioural topography to dopamine D1-like receptor agonists in mutant mice lacking the D1A receptor implicates a D1-like receptor not coupled to adenylyl cyclase , 1999, Neuroscience.
[19] B. Everitt,et al. Selective inhibition of cocaine-seeking behaviour by a partial dopamine D3 receptor agonist , 1999, Nature.
[20] J. Brosius,et al. Potentiation of the D2 mutant motor phenotype in mice lacking dopamine D2 and D3 receptors , 1999, Neuroscience.
[21] J. Crabbe,et al. Genetics of mouse behavior: interactions with laboratory environment. , 1999, Science.
[22] R. Depoortère,et al. Dopamine D3 receptor agonists produce similar decreases in body temperature and locomotor activity in D3 knock-out and wild-type mice , 1999, Neuropharmacology.
[23] F. J. White,et al. Dopamine D3 receptor mutant and wild‐type mice exhibit identical responses to putative D3 receptor‐selective agonists and antagonists , 1999, Synapse.
[24] J. Waddington,et al. SK&F 83959 and non-cyclase-coupled dopamine D1-like receptors in jaw movements via dopamine D1-like/D2-like receptor synergism. , 1999, European journal of pharmacology.
[25] J. C. Stoof,et al. The alleged dopamine D1 receptor agonist SKF 83959 is a dopamine D1 receptor antagonist in primate cells and interacts with other receptors. , 1999, European journal of pharmacology.
[26] D. Sibley,et al. New insights into dopaminergic receptor function using antisense and genetically altered animals. , 1999, Annual review of pharmacology and toxicology.
[27] D. Sibley,et al. Topographical evaluation of the phenotype of spontaneous behaviour in mice with targeted gene deletion of the D1A dopamine receptor: paradoxical elevation of grooming syntax , 1998, Neuropharmacology.
[28] S. Fuchs,et al. Human D3 dopamine receptor in the medulloblastoma TE671 cell line: cross‐talk between D1 and D3 receptors , 1998, FEBS letters.
[29] P. Sokoloff,et al. Functional implications of multiple dopamine receptor subtypes: the D1/D3 receptor coexistence 1 Published on the World Wide Web on 24 November 1997. 1 , 1998, Brain Research Reviews.
[30] P. Sokoloff,et al. Coexpression of dopamine D1 and D3 receptors in islands of Calleja and shell of nucleus accumbens of the rat: opposite and synergistic functional interactions , 1998, The European journal of neuroscience.
[31] M. Low,et al. Locomotor Activity in D2 Dopamine Receptor-Deficient Mice Is Determined by Gene Dosage, Genetic Background, and Developmental Adaptations , 1998, The Journal of Neuroscience.
[32] J. Waddington,et al. Heterogeneity of behavioural profile between three new putative selective D3 dopamine receptor antagonists using an ethologically based approach , 1998, Psychopharmacology.
[33] F. J. White,et al. Alterations in Dopamine Release But Not Dopamine Autoreceptor Function in Dopamine D3 Receptor Mutant Mice , 1998, The Journal of Neuroscience.
[34] D. Sibley,et al. Behavioral analysis of multiple D1-like dopamine receptor subtypes: new agents and studies in transgenic mice with D1A receptor knockout. , 1998, Advances in pharmacology.
[35] S. R. Nash,et al. Dopamine receptors: from structure to function. , 1998, Physiological reviews.
[36] H. Steiner,et al. D3 Dopamine Receptor-Deficient Mouse: Evidence for Reduced Anxiety , 1997, Physiology & Behavior.
[37] S. Tonegawa,et al. Dopamine D3 Receptor Mutant Mice Exhibit Increased Behavioral Sensitivity to Concurrent Stimulation of D1 and D2 Receptors , 1997, Neuron.
[38] B. Levant. The D3 dopamine receptor: neurobiology and potential clinical relevance. , 1997, Pharmacological reviews.
[39] P. Calabresi,et al. Loss of autoreceptor function in dopaminergic neurons from dopamine D2 receptor deficient mice. , 1997, Neuroscience.
[40] Allan Collins,et al. Behavioral phenotypes of inbred mouse strains: implications and recommendations for molecular studies , 1997, Psychopharmacology.
[41] R. Gerlai. Gene-targeting studies of mammalian behavior: is it the mutation or the background genotype? , 1996, Trends in Neurosciences.
[42] C. Gerfen,et al. A targeted mutation of the D3 dopamine receptor gene is associated with hyperactivity in mice. , 1996, Proceedings of the National Academy of Sciences of the United States of America.
[43] J. Waddington,et al. Pharmacological characterization of behavioural responses to SK&F 83959 in relation to ‘D1‐like’ dopamine receptors not linked to adenylyl cyclase , 1995, British journal of pharmacology.
[44] S. A. Daly,et al. Behavioural pharmacology op ‘D-1-like’ dopamine receptors: Further subtyping, new pharmacological probes and interactions with ‘D-2-like’ receptors , 1995, Progress in Neuro-Psychopharmacology and Biological Psychiatry.
[45] C. Marsden,et al. Stimulation of adenylate cyclase activity by benzazepine D-1 dopamine agonists with varying efficacies in the 6-hydroxydopamine lesioned rat--relationship to circling behaviour. , 1995, Biochemical pharmacology.
[46] H. Sarau,et al. Evidence for a Distinct D1Like Dopamine Receptor that Couples to Activation of Phosphoinositide Metabolism in Brain , 1994, Journal of neurochemistry.
[47] C. Sánchez,et al. Partial and full dopamine D1 receptor agonists in mice and rats: relation between behavioural effects and stimulation of adenylate cyclase activity in vitro. , 1992, European journal of pharmacology.
[48] Bruno Giros,et al. Molecular cloning and characterization of a novel dopamine receptor (D3) as a target for neuroleptics , 1990, Nature.
[49] D. Sibley,et al. Expression of striatal D1 dopamine receptors coupled to inositol phosphate production and Ca2+ mobilization in Xenopus oocytes. , 1990, Proceedings of the National Academy of Sciences of the United States of America.
[50] F. Labrie,et al. Activity of two new potent dopaminergic agonists at the striatal and anterior pituitary levels , 1980, Neuropharmacology.